News and events
When results are so encouraging, the path is traced: one step at a time towards the cure ~ Hemera’s Team
Innovation Coffee: Advancements in REMaST® Therapy and the Mission to Regenerate Nervous Tissue.
In the context of the "Healing the Incurable" Innovation Coffee, our CEO Cristiana Vignoli enthusiastically shared significant progress in the...
Scientific Venture Capital Selects Hemera Among Italy’s Most Innovative Deep-Tech Companies
Significant Recognition for REMaST® Therapy, a New Perspective for Medullo-Injured Patients Hemera has been chosen among the most innovative...
A study has been initiated to observe patients with traumatic and complete spinal cord injury.
The patients will be monitored for 12 months at three Centers of Excellence in Northern Italy. At the starting blocks is the prospective...
Hemera Pharma: Excellence and Innovation Recognized with Women Startup Award in Regenerative Medicine
Hemera Pharma Receives Women Startup Award for Excellence in Regenerative Medicine We are delighted to share Hemera Pharma's recent achievements in...
2nd Quarter 2023
Hemera Pharma among the 50 most innovative companies of the 2023 “Premio Gamma Donna”
Hemera is among the 50 stories of companies with a high rate of innovation led by women who interpret the objective of the Premio Gamma Donna
Hemera receives Orphan Drug Designation for REMaST® therapy
REMaST® obtains from the European Commission the designation of orphan drug for acute spinal injuries
Changed the structure of the Board of Directors
Hemera extend thanks to Aldo Cocchiglia for his contribution to the company’s advancement and success
1st Quarter 2023
Interview with Cristiana Vignoli, protagonist of the month on Il CUBo
Cristiana Vignoli, CEO of Hemera is the protagonist of the month for February in the online magazine Cubo. In the beautiful interview by Luca...
Our 2022, step by step
We close a very intense year that marked significant steps forward in the development of the first cellular therapy for the treatment of acute...
Hemera concludes the 6th capital increase
Fundrasing results to date. On December 15, 2022, Hemera concludes the 6th capital increase. More than 2 million euros were raised in 18 months of...
Hemera enters a new phase and reorganizes governance and scientific team.
The framework of roles and responsibilities expands Each journey goes through different stages. Hemera enters a new phase, namely the development of...
Hemera at the Drug Discovery Day – Bologna, June 10
Miltenyi Biotec organizes an event dedicated to researchers committed every day to make revolutionary discoveries, the Drug Discovery Day. Hemera’s...
New ways to invest in Health. Hemera’s webinars
Hemera offers three webinars on the development path of its innovative cell therapy for the treatment of neurological lesions, illustrating how to...
Ethics and numbers in the Aldo Cocchiglia’s interview on 7GOLD TV channel
The interview with our Chief Executive Officer in the television show 7InPunto, aired on April 14, begins with a seemingly simple question: Who is...
Ilaria Decimo at ESU’s event on entrepreneurship and spin-off
On April 7, 2022, Dr. Ilaria Decimo, R&D Director of Hemera, spoke at the event organized by ESU in Verona about her experience in creating a...
The press speaks about Hemera after the press conference held in Verona
After the Press Conference held on Wednesday March 9, 2022 in Verona, the traditional and online press report the news of the presentation of...
Hemera case-study presented at the University of Verona
Cristiana Vignoli, Executive Director of Hemera, will be one of the speakers of the digital event organized by the University of Verona and...
Press conference presenting Hemera
Press conference presenting Hemera Presentation of an all-italian research aimed to develop a therapy for the regeneration of nervous tissue in...
Stay informed on Hemera’s latest activities with our Newsletter.